In RCT-TCZ-COVID-19 by Salvarani et al. [21] included patients with PaO2/FiO2 200-300, average being 264, with average CRP 8.2(much less elevation as compared to our cohort with average CRP of 93.75), there was no benefit in achieving primary outcome (death/ MV/ PaO2:FiO2 < 150) with tocilizumab. Here, CRP is linked to COVID-19.